# SGLT2 Inhibition in Hemodialysis

> **NCT05179668** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 220 (actual)

## Conditions studied

- Kidney Failure
- Hemodialysis
- Diabetes Mellitus, Type 2
- Chronic Kidney Disease
- Left Ventricular Hypertrophy

## Interventions

- **DRUG:** Dapagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05179668
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-01
- **Primary completion:** 2025-07-11
- **Final completion:** 2026-02-28
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05179668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05179668, "SGLT2 Inhibition in Hemodialysis". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT05179668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*